ATE309361T1 - Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz - Google Patents

Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz

Info

Publication number
ATE309361T1
ATE309361T1 AT01936423T AT01936423T ATE309361T1 AT E309361 T1 ATE309361 T1 AT E309361T1 AT 01936423 T AT01936423 T AT 01936423T AT 01936423 T AT01936423 T AT 01936423T AT E309361 T1 ATE309361 T1 AT E309361T1
Authority
AT
Austria
Prior art keywords
neuropeptide
nuclic acid
sdf
acid molecule
sequence coding
Prior art date
Application number
AT01936423T
Other languages
German (de)
English (en)
Inventor
Hans Werner Mueller
Frank Bosse
Marc Gleichmann
Clemens Gillen
Johannes Auer
Original Assignee
Neuraxo Biotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuraxo Biotec Gmbh filed Critical Neuraxo Biotec Gmbh
Application granted granted Critical
Publication of ATE309361T1 publication Critical patent/ATE309361T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/522Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01936423T 2000-06-02 2001-06-01 Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz ATE309361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10027383A DE10027383A1 (de) 2000-06-02 2000-06-02 Nukleinsäure-Molekül umfassend eine für ein Chemokin, einen Neuropeptid-Präkursor oder mindestens ein Neuropeptid kodierende Nukleinsäuresequenz
PCT/EP2001/006250 WO2001092530A1 (de) 2000-06-02 2001-06-01 Nukleinsäure-molekül umfassend eine für ein sdf-1 gamma chemokin, einen neuropeptid-präkursor oder mindestens ein neuropeptid kodierende nukleinsäuresequenz

Publications (1)

Publication Number Publication Date
ATE309361T1 true ATE309361T1 (de) 2005-11-15

Family

ID=7644466

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01936423T ATE309361T1 (de) 2000-06-02 2001-06-01 Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz

Country Status (9)

Country Link
US (2) US20030215792A1 (enExample)
EP (1) EP1287142B1 (enExample)
JP (1) JP2004521607A (enExample)
AT (1) ATE309361T1 (enExample)
AU (1) AU6233501A (enExample)
DE (2) DE10027383A1 (enExample)
DK (1) DK1287142T3 (enExample)
ES (1) ES2251483T3 (enExample)
WO (1) WO2001092530A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004232972A1 (en) * 2003-04-16 2004-11-04 Argyll Biotechnologies, Llc Prophylactic and therapeutic benefits of new class of immune stimulating peptides
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
UA96926C2 (ru) * 2005-10-31 2011-12-26 Мерк Сероно Са Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
AU2007237840A1 (en) * 2006-04-07 2007-10-25 Neuro Therapeutics Ab Survival and development of neural cells
WO2008003780A2 (en) * 2006-07-07 2008-01-10 TRÖSCHER, Herbert Use of proteins of the sdf-1-family for improvement of axonal plasticity or for axonal regeneration following lesions
US7696309B2 (en) 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2197907A2 (en) * 2007-10-15 2010-06-23 Centre National De La Recherche Scientifique-CNRS Cxcl12 gamma a chemokine and uses thereof
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5885794A (en) * 1991-05-10 1999-03-23 The Salk Institute For Biological Studies Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
CA2117953C (en) * 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6114502A (en) * 1996-04-10 2000-09-05 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
EP0892807A1 (en) * 1996-04-10 1999-01-27 Axys Pharmaceuticals, Inc. Gene family associated with neurosensory defects
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
WO1999055915A2 (en) * 1998-04-29 1999-11-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services IDENTIFICATION OF POLYMORPHISMS IN THE PCTG4 REGION OF Xq13
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
AU2201801A (en) * 1999-12-16 2001-06-25 Ribotargets Limited Assays

Also Published As

Publication number Publication date
EP1287142A1 (de) 2003-03-05
JP2004521607A (ja) 2004-07-22
WO2001092530A1 (de) 2001-12-06
AU6233501A (en) 2001-12-11
EP1287142B1 (de) 2005-11-09
DK1287142T3 (da) 2006-03-13
US20030215792A1 (en) 2003-11-20
US20080319165A1 (en) 2008-12-25
DE50108009D1 (de) 2005-12-15
ES2251483T3 (es) 2006-05-01
DE10027383A1 (de) 2001-12-20

Similar Documents

Publication Publication Date Title
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
HUP0103758A2 (hu) Neurotróf faktorok
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
EA200601121A1 (ru) Мутеины фактора роста фибробластов 21
WO2004000997A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003057158A3 (en) Method of treating apoptosis and compositions thereof
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
ATE309361T1 (de) Nukleinsaure-molekul umfassend eine fur ein sdf-1 gamma chemokin,einen neuropeptid-prakursor oder mindestens ein neuropeptid kodierende nukleinsauresequenz
ATE70280T1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PT832233E (pt) Quimiocina beta-13 humana
BR0108654A (pt) Composição imunogênica, polipeptìdeo isolado, vetor de expressão ou um microorganismo vivo recombinante, célula hospedeira, processos para produzir uma composição imunogênica e um polipeptìdeo ou um fragmento imunogênico do mesmo, uso de um polipeptìdeo ou de um polinucleotìdeo que codifica um polipeptìdeo, método para o tratamento de um indivìduo pela imunoprofilaxia ou terapia, anticorpo, agonista ou antagonista ao polipeptìdeo, composto, e, processos para diagnosticar, uma doença ou uma suscetibilidade a uma doença e a presença de câncer colorretal ou uma suscetibilidade ao câncer colorretal, em um indivìduo
EA200100264A1 (ru) Ангиоцидин: адгезионный рецептор опухолей клетки, специфический для cys-ser-val-thr-cys-gly
MY141459A (en) Recombinant anti-idiotypic antibodies
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
AR019864A1 (es) Proceso para producir el antigeno de toxoplasma sag1 o fragmentos del mismo; proteina sag1 o fragmentos de la misma expresada en dicho proceso;composiciones de vacuna que comprendan dicha proteina sag1 o fragmentos de la misma; uso de dicha proteina para la manufactura de medicamentos para preveniry
ATE554793T1 (de) Konjugat
RU2010126590A (ru) Новые аллергены пшеницы
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002090991A3 (en) Proteins and genes for diagnosis and treatment of erbb2-related cancer
TUINMAN et al. Analysis of the amino acid sequence of peptides by mass spectrometry An ion notation proposal
DE502004008729D1 (de) Gegen das Prothrombin-Fragment F1+2 gerichtete Antikörper, ihre Herstellung und Verwendung

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee